237 related articles for article (PubMed ID: 32210016)
1. VLA-4 Expression and Activation in B Cell Malignancies: Functional and Clinical Aspects.
Härzschel A; Zucchetto A; Gattei V; Hartmann TN
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32210016
[TBL] [Abstract][Full Text] [Related]
2. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
3. Targeting the B-cell receptor signaling pathway in B lymphoid malignancies.
Buchner M; Müschen M
Curr Opin Hematol; 2014 Jul; 21(4):341-9. PubMed ID: 24811161
[TBL] [Abstract][Full Text] [Related]
4. Bruton Tyrosine Kinase Inhibitors: Present and Future.
Burger JA
Cancer J; 2019; 25(6):386-393. PubMed ID: 31764119
[TBL] [Abstract][Full Text] [Related]
5. Methods for Investigating VLA-4 (CD49d/CD29) Expression and Activation in Chronic Lymphocytic Leukemia and Its Clinical Applications.
Zucchetto A; Tissino E; Chigaev A; Hartmann TN; Gattei V
Methods Mol Biol; 2019; 1881():101-112. PubMed ID: 30350200
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the activation state of alpha4beta1 integrin in human B cell lines derived from myeloma, leukemia or lymphoma.
García-Gila M; Cabañas C; García-Pardo A
FEBS Lett; 1997 Dec; 418(3):337-40. PubMed ID: 9428740
[TBL] [Abstract][Full Text] [Related]
7. B-cell receptor signaling inhibitors for treatment of autoimmune inflammatory diseases and B-cell malignancies.
Puri KD; Di Paolo JA; Gold MR
Int Rev Immunol; 2013 Aug; 32(4):397-427. PubMed ID: 23886342
[TBL] [Abstract][Full Text] [Related]
8. Role of the tumor microenvironment in mature B-cell lymphoid malignancies.
Fowler NH; Cheah CY; Gascoyne RD; Gribben J; Neelapu SS; Ghia P; Bollard C; Ansell S; Curran M; Wilson WH; O'Brien S; Grant C; Little R; Zenz T; Nastoupil LJ; Dunleavy K
Haematologica; 2016 May; 101(5):531-40. PubMed ID: 27132279
[TBL] [Abstract][Full Text] [Related]
9. Functional and Clinical Significance of the Integrin Alpha Chain CD49d Expression in Chronic Lymphocytic Leukemia.
Dal Bo M; Tissino E; Benedetti D; Caldana C; Bomben R; Poeta GD; Gaidano G; Rossi FM; Bulian P; Zucchetto A; Gattei V
Curr Cancer Drug Targets; 2016; 16(8):659-668. PubMed ID: 27514846
[TBL] [Abstract][Full Text] [Related]
10. CXCR4- and BCR-triggered integrin activation in B-cell chronic lymphocytic leukemia cells depends on JAK2-activated Bruton's tyrosine kinase.
Montresor A; Toffali L; Rigo A; Ferrarini I; Vinante F; Laudanna C
Oncotarget; 2018 Oct; 9(80):35123-35140. PubMed ID: 30416684
[TBL] [Abstract][Full Text] [Related]
11. The emerging role of estrogen in B cell malignancies.
Ladikou EE; Kassi E
Leuk Lymphoma; 2017 Mar; 58(3):528-539. PubMed ID: 27557932
[TBL] [Abstract][Full Text] [Related]
12. Adhesion receptors on peripheral blood leukemic B cells. A comparative study on B cell chronic lymphocytic leukemia and related lymphoma/leukemias.
Csanaky G; Matutes E; Vass JA; Morilla R; Catovsky D
Leukemia; 1997 Mar; 11(3):408-15. PubMed ID: 9067581
[TBL] [Abstract][Full Text] [Related]
13. Adhesion molecules VLA-1 to VLA-6 define discrete stages of peripheral B lymphocyte development and characterize different types of B cell neoplasia.
Möller P; Eichelmann A; Koretz K; Mechtersheimer G
Leukemia; 1992 Apr; 6(4):256-64. PubMed ID: 1588789
[TBL] [Abstract][Full Text] [Related]
14. Activation of Protein Tyrosine Phosphatase Receptor Type γ Suppresses Mechanisms of Adhesion and Survival in Chronic Lymphocytic Leukemia Cells.
Montresor A; Toffali L; Fumagalli L; Constantin G; Rigo A; Ferrarini I; Vinante F; Laudanna C
J Immunol; 2021 Jul; 207(2):671-684. PubMed ID: 34162728
[TBL] [Abstract][Full Text] [Related]
15. cROSsing the Line: Between Beneficial and Harmful Effects of Reactive Oxygen Species in B-Cell Malignancies.
Domka K; Goral A; Firczuk M
Front Immunol; 2020; 11():1538. PubMed ID: 32793211
[TBL] [Abstract][Full Text] [Related]
16. Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells.
Tian YF; Ahn H; Schneider RS; Yang SN; Roman-Gonzalez L; Melnick AM; Cerchietti L; Singh A
Biomaterials; 2015 Dec; 73():110-9. PubMed ID: 26406451
[TBL] [Abstract][Full Text] [Related]
17. BCR/Integrin Interaction in CLL: A Physiologic Remnant with Clinical Relevance.
Tissino E; Bomben R; Gattei V; Zucchetto A
Clin Cancer Res; 2023 Sep; 29(18):3560-3562. PubMed ID: 37439706
[TBL] [Abstract][Full Text] [Related]
18. B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.
Koehrer S; Burger JA
Clin Adv Hematol Oncol; 2016 Jan; 14(1):55-65. PubMed ID: 27057669
[TBL] [Abstract][Full Text] [Related]
19. Distinct roles for phosphoinositide 3-kinases γ and δ in malignant B cell migration.
Ali AY; Wu X; Eissa N; Hou S; Ghia JE; Murooka TT; Banerji V; Johnston JB; Lin F; Gibson SB; Marshall AJ
Leukemia; 2018 Sep; 32(9):1958-1969. PubMed ID: 29479062
[TBL] [Abstract][Full Text] [Related]
20. Differential bone marrow homing capacity of VLA-4 and CD38 high expressing chronic lymphocytic leukemia cells.
Brachtl G; Sahakyan K; Denk U; Girbl T; Alinger B; Hofbauer SW; Neureiter D; Hofbauer JP; Egle A; Greil R; Hartmann TN
PLoS One; 2011; 6(8):e23758. PubMed ID: 21876768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
